COVID-19: Agencies Are Taking Steps to Improve Future Use of Defense Production Act Authorities, Report to Congressional Committees [open pdf - 1MB]
From the Highlights: "COVID-19 [coronavirus disease 2019] put the U.S. health care system under severe strain, affecting federal agencies' ability to buy and maintain critical medical supplies to help treat patients and protect health care workers. The federal government's COVID-19 response included a significant use of DPA [Defense Production Act] authorities, as well as other actions focused on expanding domestic production of medical supplies to help stabilize the medical supply chain. The CARES [Coronavirus Aid, Relief, and Economic Security Act] Act and other supplemental appropriations provided at least $11 billion for DPA purchases and other actions related to COVID-19 or other public health emergencies through September 2025. The CARES Act includes a provision for GAO [Government Accountability Office] to monitor funds provided for the COVID-19 pandemic. This report summarizes federal agencies' use of the DPA to respond to COVID-19 and industry perspectives, as well as implementation challenges and steps agencies have taken to address these challenges. This report summarizes information contained in reports issued in June [hyperlink], September [hyperlink], and November [hyperlink] 2020, and January [hyperlink], March [hyperlink], April [hyperlink] and July [hyperlink] 2021, and provides data updates through September 2021."
Government Accountability Office: http://www.gao.gov/